Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 2
1978 2
1979 3
1980 2
1981 2
1982 3
1983 6
1984 5
1985 4
1986 15
1987 11
1988 7
1989 2
1990 3
1991 2
1992 5
1993 12
1994 8
1995 8
1996 10
1997 9
1998 9
1999 13
2000 9
2001 13
2002 12
2003 11
2004 13
2005 9
2006 6
2007 7
2008 7
2009 6
2010 8
2011 9
2012 15
2013 8
2014 6
2015 17
2016 17
2017 15
2018 12
2019 22
2020 44
2021 29
2022 33
2023 30
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

487 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Nakachi K, et al. Among authors: morinaga s. Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4. Lancet. 2023. PMID: 36681415 Clinical Trial.
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Uesaka K, et al. Among authors: morinaga s. Lancet. 2016 Jul 16;388(10041):248-57. doi: 10.1016/S0140-6736(16)30583-9. Epub 2016 Jun 2. Lancet. 2016. PMID: 27265347 Clinical Trial.
Incorporation of human iPSC-derived stromal cells creates a pancreatic cancer organoid with heterogeneous cancer-associated fibroblasts.
Takeuchi K, Tabe S, Takahashi K, Aoshima K, Matsuo M, Ueno Y, Furukawa Y, Yamaguchi K, Ohtsuka M, Morinaga S, Miyagi Y, Yamaguchi T, Tanimizu N, Taniguchi H. Takeuchi K, et al. Among authors: morinaga s. Cell Rep. 2023 Nov 28;42(11):113420. doi: 10.1016/j.celrep.2023.113420. Epub 2023 Nov 12. Cell Rep. 2023. PMID: 37955987 Free article.
Association of longer telomere length in cancer cells and cancer-associated fibroblasts with worse prognosis.
Matsuda Y, Ye J, Yamakawa K, Mukai Y, Azuma K, Wu L, Masutomi K, Yamashita T, Daigo Y, Miyagi Y, Yokose T, Oshima T, Ito H, Morinaga S, Kishida T, Minamoto T, Kojima M, Kaneko S, Haba R, Kontani K, Kanaji N, Okano K, Muto-Ishizuka M, Yokohira M, Saoo K, Imaida K, Suizu F. Matsuda Y, et al. Among authors: morinaga s. J Natl Cancer Inst. 2023 Feb 8;115(2):208-218. doi: 10.1093/jnci/djac226. J Natl Cancer Inst. 2023. PMID: 36567450 Free PMC article.
Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04).
Sugiura T, Toyama H, Fukutomi A, Asakura H, Takeda Y, Yamamoto K, Hirano S, Satoi S, Matsumoto I, Takahashi S, Morinaga S, Yoshida M, Sakuma Y, Iwamoto H, Shimizu Y, Uesaka K. Sugiura T, et al. Among authors: morinaga s. J Hepatobiliary Pancreat Sci. 2023 Nov;30(11):1249-1260. doi: 10.1002/jhbp.1353. Epub 2023 Sep 25. J Hepatobiliary Pancreat Sci. 2023. PMID: 37746781 Clinical Trial.
Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis.
Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Taniguchi Y, Morinaga S, Sone T, Okuda M, Matsumoto I, Yano S, Tsuchiya H. Asano Y, et al. Among authors: morinaga s. Cancer Med. 2023 Jun;12(11):12425-12437. doi: 10.1002/cam4.5952. Epub 2023 Apr 19. Cancer Med. 2023. PMID: 37076988 Free PMC article.
[Myelofibrosis].
Morinaga S, Muto Y. Morinaga S, et al. Ryoikibetsu Shokogun Shirizu. 2000;(32):425-7. Ryoikibetsu Shokogun Shirizu. 2000. PMID: 11212764 Review. Japanese. No abstract available.
487 results